Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
2.
Bone Marrow Transplant ; 57(5): 742-752, 2022 05.
Article in English | MEDLINE | ID: covidwho-1702554

ABSTRACT

In 2020, 45,364 HCT in 41,016 patients, 18,796 (41%) allogeneic and 26,568 (59%) autologous in 690 centers were reported. Changes observed were as follows: total number of HCT -6.5%, allogeneic HCT -5.1%, autologous HCT -7.5%, and were more pronounced in non-malignant disorders for allogeneic HCT and in autoimmune disease for autologous HCT. Main indications were myeloid malignancies 10,441 (25%), lymphoid malignancies 26,120 (64%) and non-malignant disorders 2532 (6%). A continued growth in CAR-T cellular therapies to 1874 (+65%) patients in 2020 was observed. In allogeneic HCT, the use of haploidentical donors increased while use of unrelated and sibling donors decreased. Cord blood HCT increased by 11.7% for the first time since 2012. There was a significant increase in the use of non-myeloablative but a drop in myeloablative conditioning and in use of marrow as stem cell source. We interpreted these changes as being due to the SARS-CoV-2 pandemic starting early in 2020 in Europe and provided additional data reflecting the varying impact of the pandemic across selected countries and larger cities. The transplant community confronted with the pandemic challenge, continued in providing patients access to treatment. This annual report of the EBMT reflects current activities useful for health care planning.


Subject(s)
COVID-19 , Hematopoietic Stem Cell Transplantation , Neoplasms , Europe/epidemiology , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Neoplasms/etiology , Pandemics , SARS-CoV-2 , Transplantation, Homologous
4.
Bone Marrow Transplant ; 55(11): 2071-2076, 2020 11.
Article in English | MEDLINE | ID: covidwho-260560

ABSTRACT

The new coronavirus SARS-CoV-2 has rapidly spread over the world causing the disease by WHO called COVID-19. This pandemic poses unprecedented stress on the health care system including programs performing allogeneic and autologous hematopoietic cell transplantation (HCT) and cellular therapy such as with CAR T cells. Risk factors for severe disease include age and predisposing conditions such as cancer. The true impact on stem cell transplant and CAR T-cell recipients in unknown. The European Society for Blood and Marrow Transplantation (EBMT) has therefore developed recommendations for transplant programs and physicians caring for these patients. These guidelines were developed by experts from the Infectious Diseases Working Party and have been endorsed by EBMT's scientific council and board. This work intends to provide guidelines for transplant centers, management of transplant candidates and recipients, and donor issues until the COVID-19 pandemic has passed.


Subject(s)
Betacoronavirus , Coronavirus Infections , Delivery of Health Care/standards , Hematopoietic Stem Cell Transplantation , Immunotherapy, Adoptive , Infection Control/standards , Pandemics , Pneumonia, Viral , Accreditation/organization & administration , Allografts , COVID-19 , COVID-19 Testing , Clinical Laboratory Techniques , Continuity of Patient Care , Coronavirus Infections/diagnosis , Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Cross Infection/prevention & control , Europe , Health Personnel , Hematopoietic Stem Cell Transplantation/methods , Hematopoietic Stem Cell Transplantation/statistics & numerical data , Humans , Immunocompromised Host , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Infectious Disease Transmission, Professional-to-Patient/prevention & control , Office Visits , Pandemics/prevention & control , Pneumonia, Viral/diagnosis , Pneumonia, Viral/epidemiology , Pneumonia, Viral/prevention & control , Procedures and Techniques Utilization , SARS-CoV-2 , Telemedicine , Tissue Donors , Transplant Recipients , Transplantation, Autologous , Visitors to Patients
SELECTION OF CITATIONS
SEARCH DETAIL